Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients.

doi:10.1111/bcpt.13368

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients.

Basic & clinical pharmacology & toxicology - 1 May 2020

Ximenez João P, Lanchote Vera L, Bello Marcelo A, Iocken Fernanda H S, Obadia Renata C M, de Sousa Valéria P, Suarez-Kurtz Guilherme

Abstract excerpt

Generic formulations of tamoxifen are commonly prescribed to oestrogen receptor-positive breast cancer patients at the Brazilian National Cancer Institute (INCA). We carried out a post-marketing surveillance of the generic tamoxifen formulation in current use at INCA, by comparing plasma concentrations of the parent drug and metabolites obtained with the generic vs the reference formulation. Thirty patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Hormonal
Share to Brazil
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Tamoxifen

Source

Open in PubMed

Identifiers

PMID: 31758654
DOI: 10.1111/bcpt.13368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.